The Finnish engineering and consulting company is in charge of the design of two vaccine production plants to be built in South India. The aim is for the first plant to be operational in late 2021.
The global demand for COVID vaccines exceeds the supply. Elomatic is involved in easing the global shortage of COVID vaccines by taking charge of the design of two vaccine production plants in South India.
The UN, among others, has emphasised India’s potential as a vaccine producer in the COVID-19 pandemic. Elomatic has an office also in India, so it was possible to begin the work efficiently already last year,” says Elomatic CEO Patrik Rautaheimo.
“There will be an annual need for COVID vaccines, like influenza vaccines, which means manufacturing capacity has to be increased aggressively, both globally and nationally,” says Markku S. Lehtinen, Senior Vice President, Process & Energy at Elomatic.
The first production plant will focus on the mass production of COVID vaccines. The client is one of the leading Indian producers of vaccines, with a significant share of exports. The plant is scheduled for completion in late 2021.
The second COVID vaccine plant will be completed in March 2022. The plant was ordered by an international vaccine manufacturer that co-operates closely with WHO and UNICEF.
The vaccines produced in India are to be exported to Australia, the United States, APAC, Africa and possibly other regions.
For further information, please contact
Markku S. Lehtinen, Senior Vice President, Elomatic
+358 40 833 8959
Elomatic is an engineering and consulting company that focuses on solutions that improve the well-being of people and the environment. Elomatic employs more than 1,100 professionals in 13 countries.